Arkayli Biopharma
Private Company
Total funding raised: $5M
Overview
Arkayli Biopharma is a privately held, pre-revenue biotech founded in 2021 and based in San Diego, CA. The company is advancing ARK001, a once-daily topical formulation for infantile hemangioma (IH), which is currently in the preclinical stage with the potential to become the first FDA-approved non-systemic treatment for this condition. Arkayli leverages a seasoned leadership team with deep expertise in drug development, dermatology, and commercialization. Its strategy focuses on addressing a clear unmet need in pediatric dermatology through a localized, convenient therapy designed to improve patient and caregiver experiences.
Technology Platform
Proprietary topical drug delivery system designed for localized, sustained 24-hour action from a single daily application with minimal systemic exposure.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
The current standard of care is oral propranolol, a systemic therapy with known side-effects. Topical timolol is used off-label but has limitations in penetration and dosing. Arkayli aims to compete by offering a first-in-class, FDA-approved topical product designed for superior localized delivery and convenience, potentially capturing market share from both systemic and off-label topical treatments.